<PAGE>
                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington D.C. 20549

                                 FORM 10-K/A
                               Amendment No. 1

[X]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the fiscal year ended                                    June 30, 2008
                                                           ------------------
                                     or

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from                       to
                              -----------------------  ----------------------

Commission File No.                              0-21419
                                          -----------------------------------

                             Cardo Medical, Inc.
---------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

               Delaware                                  23-2753988
---------------------------------------------------------------------------
     (State or other jurisdiction of                  (IRS Employer
      incorporation or organization)               Identification No.)

8899 Beverly Boulevard, Suite 619, Los Angeles, California            90048
---------------------------------------------------------------------------
(Address of principal executive offices)                       (Zip Code)

                                                         (310) 274-2036
Registrant's Telephone Number, including area code --------------------------

Securities registered pursuant to section 12(b) of the Act:

     Title of each class            Name of each exchange on which registered

----------------------------------  -----------------------------------------

----------------------------------  -----------------------------------------

           Securities registered pursuant to section 12(g) of the Act:

                        Common Stock, par value $.001
-----------------------------------------------------------------------------
                              (Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act.                    [ ] Yes  [X] No

Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or 15(d) of the Act.                   [ ] Yes  [X] No
<PAGE>
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.                [X] Yes  [ ] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K (Section 229.405 of this chapter) is not contained
herein and will not be contained, to the best of registrant's knowledge, in
definitive proxy or information statements incorporated by reference in Part
III of this Form 10-K or any amendment to this Form 10-K                  [ ]

Indicate by check mark whether the registrant is a large accelerated filer, a
non-accelerated filer, or a smaller reporting company.  See the definitions
of "large accelerated filer," "accelerated filer" and "smaller reporting
company" in Rule 12b-2 of the Exchange Act.

  Large accelerated filer  [ ]                         Accelerated filer  [ ]
  Non-accelerated filer    [ ]                 Smaller reporting company  [X]

Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Act).                                    [X] Yes  [ ] No

State the aggregate market value of the voting and non-voting common equity
held by non-affiliates computed by reference to the price at which the common
equity was last sold, or the average bid and asked price of such common
equity, as of the last business day of the registrant's most recently
completed second fiscal quarter.                           $11,023,368
                                                      -----------------------

The Registrant had 203,360,222 shares of common stock, par value $.001,
outstanding as of September 19, 2008.





















                                      2
<PAGE>

EXPLANATORY NOTE

     Cardo Medical, Inc. (the "Company," "we," "us," "our" or "Cardo") is
filing this Amendment No. 1 to its Annual Report on Form 10-K for the year
ended June 30, 2008, filed with the Securities and Exchange Commission (the
"SEC") on September 29, 2008 (the "Original Filing") to include in Item 9A(T)
management's conclusion that, based on an assessment conducted by our former
principal executive officer and former principal financial officer in
connection with such filing, our internal control over financial reporting
operated effectively at June 30, 2008.  This conclusion was inadvertently
omitted from the Original Filing.  This Form 10-K/A continues to speak as of
the date of the Original Filing, September 29, 2008.  As reported herein,
clickNsettle.com, Inc. merged with Cardo on August 29, 2008.  Our post-merger
officers and directors are filing and certifying this Amendment.


Item 9A(T).  CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures


     Disclosure controls and procedures mean the methods designed to ensure
that information that the Company is required to disclose in the reports that
it files with the Securities and Exchange Commission is recorded, processed,
summarized and reported within the time periods required.  Our controls and
procedures are designed to ensure that all information required to be
disclosed is accumulated and communicated to our management to allow timely
decisions regarding disclosure.



     Under the supervision and with the participation of our management,
including our principal executive officer and principal financial officer, we
conducted an evaluation of the effectiveness of the design and operation of
our disclosure controls and procedures, as defined in Rules 13a-15(e) and
15d-15(e) under the Securities Exchange Act of 1934, as of June 30, 2008.
Based on this evaluation, our principal executive officer and principal
financial officer concluded that our disclosure controls and procedures were
effective as of the end of the period covered by this report.



Management's report on internal control over financial reporting



     Our controls and procedures are designed to provide reasonable assurance
of the reliability of our financial reporting and accurate recording of our
financial transactions.  Our management is responsible for establishing and
maintaining adequate internal control over financial reporting.  Under the
supervision and with the participation of the Company's management, including



                                      3
<PAGE>
the principal executive officer and the principal financial officer, the
Company's management conducted an evaluation of the effectiveness of its
internal control over financial reporting as of June 30, 2008 as required by
the Securities Exchange Act of 1934 Rule 13a-15(c).  Our management assessed
the risks associated with the reliability of our financial reporting by
identifying the risks that could result in a misstatement in our financial
statements.  In making this assessment, the Company's management used the
criteria set forth in the framework in "Internal Control-Integrated
framework" issued by the Committee of Sponsoring Organizations of the
Treadway Commission.  No material weaknesses in our internal control over
financial reporting were identified, and our principal executive officer and
principal financial officer concluded that the Company has controls in place
that address our financial reporting risks and that such controls operated
effectively as of June 30, 2008.


     This Annual Report on Form 10-K does not include an attestation report
of the Company's registered public accounting firm regarding internal control
over financial reporting.  Management's report was not subject to attestation
by the Company's registered public accounting firm pursuant to temporary
rules of the Securities and Exchange Commission that permit the Company to
provide only management's report in this annual report.


Changes in internal control over financial reporting



     Based on an evaluation, under the supervision and with the participation
of our management, including our principal executive officer and principal
financial officer, there has been no significant change in our internal
controls over financial reporting during our last fiscal quarter identified
in connection with that evaluation that materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.


     A control system, however well designed and operated, can provide only
reasonable, not absolute, assurance that the control system's objectives will
be met.  There are inherent limitations in all control systems, and no
evaluation of controls can provide absolute assurance that all control gaps
or instances of fraud have been detected.  These inherent limitations include
the realities that the judgments in decision-making can be faulty, and that
simple errors or mistakes can occur.


Cardo Medical's pre-merger disclosure controls and procedures and internal
control over financial reporting.



     Prior to the merger of CKST and Cardo, Cardo identified material
weaknesses in its disclosure controls and procedures and its internal control
over financial reporting as of December 31, 2007 and, accordingly, concluded


                                      4
<PAGE>
that its disclosure controls and procedures and internal control over
financial reporting were not effective as of that date.  Cardo has reported
these weaknesses and its efforts to mitigate and remediate these weaknesses
in its filings with the SEC.



















































                                      5
<PAGE>
ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES
<TABLE>
<CAPTION>
Exhibit No. Document
-----------  ----------------------------------------------------------------
<S>         <C>
2.1(1)      Merger Agreement and Plan of Reorganization, dated as of June 18,
            2008, by and among clickNsettle.com, Inc., Cardo Medical, LLC and
            Cardo Acquisition, LLC
2.2(2)      First Amendment to Merger Agreement and Plan of Reorganization,
            dated as of August 29, 2008, by and among clickNsettle.com, Inc.,
            Cardo Medical, LLC and Cardo Acquisition, LLC
3.1(3)      Amended and Restated Certificate of Incorporation
3.2(4)      Amended and Restated Bylaws
10.6(5)     Stock Purchase Agreement, dated as of December 19, 2007, by and
            among clickNsettle.com, Inc., Frost Gamma Investments Trust, Dr.
            Jane Hsiao, Steven D. Rubin and Subbarao Uppaluri
10.7(4)     First Amendment to Stock Purchase Agreement, dated as of January
            31, 2008, by and among clickNsettle.com, Inc., Frost Gamma
            Investments Trust, Dr. Jane Hsiao, Steven D. Rubin and Subbarao
            Uppaluri
21.1(2)     Subsidiaries of clickNsettle.com, Inc.
31.1        Certification of Chief Executive Officer
31.2        Certification of Chief Financial Officer
32          Certification Pursuant to Rule 13a-14(b) and Section 906 of the
            Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section
            1350, Title 18, United Sates Code)
---------------------
<FN>
(1) Previously filed as an exhibit to the Current Report on Form 8-K filed by
us on June 23, 2008.
(2) Previously filed as an exhibit to the Current Report on Form 8-K filed by
us on September 9, 2008.
(3) Previously filed as an exhibit to the Current Report on Form 8-K filed by
us on March 18, 2008.
(4) Previously filed as an exhibit to the Current Report on Form 8-K filed by
us on February 1, 2008.
(5) Previously filed as an exhibit to the Current Report on Form 8-K filed by
us on December 21, 2007.
</FN>
</TABLE>














                                     6
<PAGE>
SIGNATURES
     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.


                                         CARDO MEDICAL, INC.


Dated:  January 28, 2009                 By: /s/Andrew Brooks
                                         ------------------------------------
                                         Chief Executive Officer
                                         (principal executive officer)




Dated:  January 28, 2009                 By:/s/Derrick Romine
                                         ------------------------------------
                                         Chief Financial Officer
                                         (principal financial officer)


































                                      7
<PAGE>
                                                                Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER


     I, Andrew Brooks, certify that:



     1.  I have reviewed this Amendment No. 1 to annual report on Form 10-K
of Cardo Medical, Inc.;

     2.  Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this report;

     3.  Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;


     4.  The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:


     a)  Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being
prepared;

     b)  Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
     c)  Evaluated the effectiveness of the registrant's disclosure controls
and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and

     d)  Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial
reporting; and

                                      8
<PAGE>

     5.  The registrant's other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or persons performing the equivalent
functions):

     a)  All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record,
process, summarize and report financial information; and
     b)  Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's internal
control over financial reporting.


Dated:  January 28, 2009             /s/ Andrew Brooks
                                    ---------------------------------------
                                     Andrew Brooks
                                     Chief Executive Officer



































                                      9
<PAGE>
                                                                Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER


     I, Derrick Romine, certify that:



     1.  I have reviewed this Amendment No. 1 to annual report on Form 10-K
of Cardo Medical, Inc.;

     2.  Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this report;

     3.  Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;


     4.  The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:


     a)  Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being
prepared;

     b)  Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
     c)  Evaluated the effectiveness of the registrant's disclosure controls
and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and

     d)  Disclosed in this report any change in the registrant's internal
control over financial reporting that occurred during the registrant's most
recent fiscal quarter (the registrant's fourth fiscal quarter in the case of
an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial
reporting; and

                                      10
<PAGE>

     5.  The registrant's other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of the
registrant's board of directors (or persons performing the equivalent
functions):

     a)  All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record,
process, summarize and report financial information; and
     b)  Any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's internal
control over financial reporting.


Dated:  January 28, 2009            /s/ Derrick Romine
                                    ---------------------------------------
                                    Derrick Romine
                                    Chief Financial Officer



































                                      11
<PAGE>
                                                                Exhibit 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) AND SECTION 906 OF THE SARBANES-
OXLEY ACT OF 2002 (SUBSECTIONS (a) AND (b) OF SECTION 1350, TITLE 18, UNITED
STATES CODE)


     In connection with Amendment No. 1 to the Annual Report on Form 10-K of
Cardo Medical, Inc. for the fiscal year ended June 30, 2008, as filed with
the Securities and Exchange Commission (the "Report"), we, Andrew Brooks,
Chief Executive Officer of Cardo Medical, Inc., and Derrick Romine, Chief
Financial Officer of Cardo Medical, Inc., hereby certify pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:


     1.  The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and


     2.  The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of Cardo
Medical, Inc.




Dated:  January 28, 2009            /s/ Andrew Brooks
                                    ---------------------------------------
                                    Andrew Brooks

                                    Chief Executive Officer



Dated:  January 28, 2009            /s/ Derrick Romine
                                    ---------------------------------------
                                    Derrick Romine

                                    Chief Financial Officer









A signed original of this written statement required by Section 906 has been
provided to Cardo Medical, Inc. and will be retained by Cardo Medical, Inc.
and furnished to the Securities and Exchange Commission or its staff upon
request.